MXPA00012079A - Cyclophosphamide coated tablets - Google Patents
Cyclophosphamide coated tabletsInfo
- Publication number
- MXPA00012079A MXPA00012079A MXPA/A/2000/012079A MXPA00012079A MXPA00012079A MX PA00012079 A MXPA00012079 A MX PA00012079A MX PA00012079 A MXPA00012079 A MX PA00012079A MX PA00012079 A MXPA00012079 A MX PA00012079A
- Authority
- MX
- Mexico
- Prior art keywords
- parts
- tablet
- talc
- cyclophosphamide
- core
- Prior art date
Links
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 229960004397 Cyclophosphamide Drugs 0.000 title claims abstract description 27
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000126 substance Substances 0.000 claims abstract description 18
- 239000000454 talc Substances 0.000 claims abstract description 17
- 229910052623 talc Inorganic materials 0.000 claims abstract description 17
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 claims abstract description 14
- 229960001021 Lactose Monohydrate Drugs 0.000 claims abstract description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 13
- 229920002261 Corn starch Polymers 0.000 claims abstract description 12
- 239000008120 corn starch Substances 0.000 claims abstract description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 7
- 229920002472 Starch Polymers 0.000 claims abstract description 6
- 235000019698 starch Nutrition 0.000 claims abstract description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 4
- 239000000314 lubricant Substances 0.000 claims abstract 11
- 239000000945 filler Substances 0.000 claims abstract 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract 6
- 235000021355 Stearic acid Nutrition 0.000 claims abstract 3
- 239000011230 binding agent Substances 0.000 claims abstract 3
- BYNVYIUJKRRNNC-UHFFFAOYSA-N docosanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O BYNVYIUJKRRNNC-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000008117 stearic acid Substances 0.000 claims abstract 3
- 235000012222 talc Nutrition 0.000 claims description 16
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 11
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 11
- 235000012239 silicon dioxide Nutrition 0.000 claims description 10
- 239000000377 silicon dioxide Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000004408 titanium dioxide Substances 0.000 claims description 4
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims 7
- 239000002706 dry binder Substances 0.000 claims 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 4
- 230000001105 regulatory Effects 0.000 claims 4
- CXQXSVUQTKDNFP-UHFFFAOYSA-N Simethicone Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 claims 3
- 229940083037 Simethicone Drugs 0.000 claims 3
- -1 polysorbitol 80 Polymers 0.000 claims 3
- 125000004494 ethyl ester group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 claims 2
- 235000019798 tripotassium phosphate Nutrition 0.000 claims 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims 1
- 210000004940 Nucleus Anatomy 0.000 claims 1
- 238000007334 copolymerization reaction Methods 0.000 claims 1
- XPNLOZNCOBKRNJ-UHFFFAOYSA-N ethyl prop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C=C.COC(=O)C(C)=C XPNLOZNCOBKRNJ-UHFFFAOYSA-N 0.000 claims 1
- 230000004907 flux Effects 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- HTEAGOMAXMOFFS-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.COC(=O)C(C)=C HTEAGOMAXMOFFS-UHFFFAOYSA-N 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 235000019700 dicalcium phosphate Nutrition 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 229910052814 silicon oxide Inorganic materials 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000009114 investigational therapy Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229950002273 Simeticone Drugs 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000005020 pharmaceutical industry Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
Abstract
The invention relates to coated tablets having cyclophosphamide as active substance, containing in the core cyclophosphamide, one or more fillers, one or several dry binding agents but no pre-swollen starches, flow regulation agents and lubricants. In a preferred embodiment of the invention, the core of the film tablet contains lactose monohydrate, D-mannite or CaHPO4 as fillers, non-pre-swollen corn starch or micro fine cellulose as dry binding agents, highly dispersed silicon oxide as flow regulation agents and magnesium stearate, stearic acid, glycerin palmitostearate, polyethylene glycol, talc or glycerin monobehenate as lubricants.
Description
COATED CYCLOPHOSPHAMIDE TABLETS Description of the invention The invention relates to coated cyclophosphamide tablets, as well as to a method for their preparation. The invention has application in the pharmaceutical industry. Cyclophosphamide is a remedy with broad antitumor spectrum, introduced for decades in chemotherapy for the treatment of solid tumors such as breast cancer, bronchial cancer as well as haemoblasts. The medicinal preparations are so far tablets, dragees, as well as mainly lyophilized with various auxiliary substances, such as mannitol or urea. EP 0519099 discloses tablets containing cyclophosphamide and pre-foamed starch, manufactured by a direct tableting process. Because the cyclophosphamide is harmful to health and therefore a direct contact with this substance represents a potential risk, the tablets prepared according to EP 0519099 are used as cores for wrapping tablets, and thus are wrapped by a second tableted. This process is technically complex. In addition, special tableting machines are required for the manufacture of wrapping tablets. Accordingly, there is a need for a simple and inexpensive preparation of a solid oral drug preparation containing cyclophosphamide. In this it is important to consider that medicinal preparations must be wrapped to avoid direct contact with the cytotoxic active ingredient. Surprisingly, it was possible to prepare coated tablets containing cyclophosphamide, without using pre-foamed starch. Suitable auxiliaries were selected based on the compatibility investigations listed in Example I. Surprisingly it was found that the stability of cyclophosphamide is rather regular in the presence of pre-foamed starch. It was also surprising that the coated tablets show sufficient stability despite the fact that, due to the process, the active principle is subjected to humidity and heat during the coating process. Example 1 Investigation of the compatibility of cyclophosphamide with various tableting substances.
53.5 mg of cyclophosphamide and 86.5 mg (of auxiliary substance 1-10) and 3.0 mg (of auxiliary substance 11-18) were mixed and b in each case. The storage of the tablets was carried out at 31 ° C for 6 months. The decomposition of the active substance was carried out by determination of the chloride. The results are summarized in the following table.
continuation of the table
depending on the type
Example 2 Preparation of tablet cores (50 mg of cyclophosphamide) Direct tabletting 0.535 mg of the osfamide cycle, 0.390 mg of lactose monohydrate, 0.400 mg of microcrystalline cellulose, 0.200 mg of corn starch, 0.040 mg of talc and 0.5 mg are sieved and homogenized. 0.020 mg of highly dispersed silicon dioxide. Next, 0.015 mg of magnesium stearate is added and mixed. The dough prepared in this way is made into tablets: Weight: 160 mg Hardness: > 30 N Decomposition: < 10 minutes.
Example 3 Preparation of coated tablets (50 mg of cyclophosphamide) 11.83 g of polyethylene glycol and 2.37 g of polysorbitol 80 are dissolved in 75.21 g of water. 1.9 g of sodium carboxymethylcellulose are dissolved in 80.0 g of water. The solutions come together. Then 23.67 g of talc, 23.67 g of titanium dioxide and 0.24 g of simeticone are added and homogenized. Subsequently, 17.73 g of a water dispersion of copolymerized acrylic acid ethyl ester / methacrylic acid methyl ester are added. Next, the cores of the tablets are sprayed with the prepared suspension, with a suitable device. Theoretical weight of a coated tablet 166 mg Example 4 Investigation of the stability of coated cyclophosphamide tablets.
With a storage to < 25 ° C a stability of the coated tablets of up to 3 years is expected.
Claims (19)
- CLAIMS 1. Coated tablet comprising a core of the tablet containing cyclophosphamide as an active ingredient, as well as one or more fillers, one or more dry binders, one or more flow regulators, one or more lubricants and one suitable coating film, characterized in that in the core of the tablet at least one of the fillers is lactose monohydrate and as a dry binder it does not contain pre-foamed starch.
- 2. A coated tablet according to claim 1, characterized in that for the core of the tablet the filler substance (s) is selected from the group comprising lactose monohydrate, mannitol D and potassium phosphate, the binder (s) (s) dry are selected from the group comprising non-pre-fluffed corn starch and microcrystalline cellulose, the flux regulating agent (s) is (are) selected from the group comprising dioxides of highly dispersed silicon, and the lubricant (s) is (are) selected from the group consisting of magnesium stearate, stearic acid, palmito-glycerin stearate, polyethylene glycol, talc and glycerin monobehenate.
- 3. Coated tablets comprising a core of the tablet and a suitable coating film, characterized in that the core contains as an active principle cyclophosphamide and as auxiliary substances lactose monohydrate, non-pre-foamed corn starch, microcrystalline cellulose, high silicon dioxide dispersed, magnesium stearate and talc. Coated tablet according to one of claims 1 to 3, characterized in that 1 part of cyclophosphamide in the core of the tablet comprises, in each case, the weight: 0.2-1.5 parts of lactose monohydrate 0.2-1.5 parts of microcrystalline cellulose 0.1-1.5 parts of corn starch not pre-foamed 0.01-1.5 parts of talc 0.01-0.1 parts of highly dispersed silicon dioxide, and 0.01-0.1 parts of magnesium stearate. Coated tablet according to one of claims 1 to 4, characterized in that 1 part of cyclophosphamide in the core of the tablet comprises, in each case referred to weight: 0.5-1 parts of lactose monohydrate 0.5-1 parts of microcrystalline cellulose 0.2-0.7 parts of corn starch not pre-foamed 0.05-0.08 parts of talc 0.01-0.05 parts of highly dispersed silicon dioxide, and0. 01-0.05 parts of magnesium stearate. Coated tablet according to one of claims 1 to 5, characterized in that 1 part of cyclophosphamide in the core of the tablet comprises, in each case referred to weight: 0.73 parts of lactose monohydrate 0.74-0.75 parts of microcrystalline cellulose 0.37 parts of non-pre-foamed corn starch 0.07-0.075 parts of talc 0.037-0.04 parts of highly dispersed silicon dioxide, and 0.028-0.03 parts of magnesium stearate. Coated tablet according to one of claims 1 to 6, characterized in that the coating film comprises substances that are selected from the group comprising polyethylene glycol, polysorbitol 80, sodium carboxymethylcellulose, talc, titanium dioxide, simethicone, copolymerized ethyl ester of the acrylic acid-methacrylic acid methyl ester. 8. Tablet core containing cyclophosphamide as an active substance, as well as one or more fillers, one or more dry binders, one or more flow regulating agents and one or more lubricants, characterized in that at least one of the substances of filler is lactose monohydrate and as a dry binder it does not contain pre-foamed starch. Tablet core according to claim 8, characterized in that the filler substance (s) is (are) selected from the group comprising lactose monohydrate, mannitol D and potassium phosphate, the dry binder (s) selected from the group comprising non-pre-foamed corn starch and microcrystalline cellulose, the creep regulatory agent (s) is (are) selected from the group comprising highly dispersed silicon dioxides, and the lubricant (s) is selected from the group comprising magnesium stearate , stearic acid, palmito-glycerin stearate, polyethylene glycol, talc and glycerin monobehenate. 10. A tablet nucleus characterized in that it comprises, as an active principle, cyclophosphamide and, as auxiliary substances, lactose monohydrate, non-pre-foamed corn starch, microcrystalline cellulose, highly dispersed silicon dioxide, magnesium stearate and talc. Tablet core according to one of claims 8 to 10, characterized in that 1 part of cyclophosphamide comprises, in each case referred to weight: 0.2-1.5 parts of lactose monohydrate 0.2-1.5 parts of microcrystalline cellulose0. 1-1.5 parts of corn starch not pre-foamed 0.01-1.5 parts of talc 0.01-0.1 parts of highly dispersed silicon dioxide, and 0.01-0.1 parts of magnesium stearate. Tablet core according to one of claims 8 to 11, characterized in that 1 part of cyclophosphamide comprises, in each case referred to weight: 0.5-1 parts of lactose monohydrate 0.5-1 parts of microcrystalline cellulose 0.2-0.7 parts of corn starch not pre-foamed 0.05-0.08 parts of talc 0.01-0.05 parts of highly dispersed silicon dioxide, and 0.01-0.05 parts of magnesium stearate. 13. Tablet core according to one of claims 8 to 12, characterized in that 1 part of cyclophosphamide comprises, in each case referred to weight: 0.73 parts of lactose monohydrate 0.74-0.75 parts of microcrystalline cellulose 0.37 parts of corn starch not pre-foamed 0.07-0.075 parts of talc 0.037-0.04 parts of highly dispersed silicon dioxide, and0. 028-0.03 parts magnesium stearate. 14. Coated tablet, characterized in that it is obtained by providing a suitable coating film in a tablet core according to claims 8 to 13. 15. Coated tablet according to claim 14, characterized in that the coating film comprises substances that are selected from the group that it comprises polyethylene glycol, polysorbitol 80, sodium carboxymethylcellulose, talc, titanium dioxide, simethicone, copolymerized acrylic acid ethyl ester methacrylic acid methyl ester and water. 16. Method for manufacturing tablet cores according to claims 8 to 13, characterized in that it comprises respectively the steps of screening and collecting cyclophosphamide, the filler substance (s), the dry binder (s), the or the regulating agent (s) of the fluence and a part of the lubricant (s), homogenizing the mixture thus obtained, sifting and adding the remaining lubricant (s), mixing the mixture obtained in this way and compressing the mass obtained in this way to tablet cores. 17. Method according to claim 16, characterized in that in the step of sifting and gathering, talc is added as a lubricant and in the step of sifting and adding the remaining lubricants, magnesium stearate is added as a lubricant. 18. Method for the production of coated tablets, characterized in that the tablet cores obtained according to claims 16 or 17 are sprayed with a suitable coating suspension. The method according to claim 18, characterized in that the coating substance comprises substances that are selected from the group comprising polyethylene glycol, polysorbitol 80, sodium-carboxymethylcellulose, talc, titanium dioxide, simethicone, copolymerization of ethyl ester of acrylic acid-methyl ester of methacrylic acid and water.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19826517.4 | 1998-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00012079A true MXPA00012079A (en) | 2002-03-05 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI113336B (en) | Process for the preparation of tramadol salt containing drug with sustained release of active substance | |
AU600950B2 (en) | Controlled release dihydrocodeine composition | |
US4454108A (en) | Prolonged-action multiple-layer tablets | |
CA1315202C (en) | Oral sustained release acetaminophen formulation and process | |
AU677595B2 (en) | Sustained release tablets containing bupropion | |
EP0290168A1 (en) | Ibuprofen sustained release matrix and process | |
WO1995021607A1 (en) | Controlled release hydrogel formulation | |
JPH0753364A (en) | Persistent release using hpmc with high and low viscosities | |
KR20010086062A (en) | Sustained release matrix systems for highly soluble drugs | |
AU748396B2 (en) | Composition | |
EP0348688B1 (en) | Solid pharmaceutical preparation and method of producing same | |
JPH06206833A (en) | Pharmaceutical drug | |
AU751117B2 (en) | Novel oral dosage form for carvedilol | |
CA2333682C (en) | Cyclophosphamide film-coated tablets | |
CA2048367C (en) | Solid oral forms of application containing ifosfamide as active substance | |
IE883032L (en) | Pharmaceutical compositions comprising a piperidinoalkanol | |
IE903330A1 (en) | An analgesic composition and a method for its formulation | |
WO2010149794A2 (en) | Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane) | |
MXPA00012079A (en) | Cyclophosphamide coated tablets | |
EP1815850A1 (en) | Controlled release formulation of divalproic acid and its derivatives | |
JP4696210B2 (en) | Sustained-release tablets containing isosorbide-5-mononitrate as an active ingredient and method for producing the same | |
CN109195609A (en) | Tablet packet troche medical composition comprising cyclophosphamide and capecitabine | |
JPS60228410A (en) | Long-acting drug preparation | |
WO2004024138A1 (en) | Solid preparation containing dioctyl sodium sulfosuccinate | |
WO2004058152A2 (en) | An extended release pharmaceutical composition of phenytoin sodium |